Skip to main content
Novartis AG logo

Novartis AG — Investor Relations & Filings

Ticker · NOVN ISIN · CH0038459415 LEI · 5493007HIVTX6SY6XD66 SW Manufacturing
Open in API
Filings indexed 1,070 across all filing types
Latest filing 2017-11-14 Regulatory Filings
Country CH Switzerland
Listing SW NOVN

About Novartis AG

https://www.novartis.com/

Novartis AG is a global medicines company focused on the research, development, manufacturing, and marketing of innovative healthcare products. The company's mission is to reimagine medicine to improve and extend people's lives. By leveraging advanced science and technology, Novartis develops a portfolio of treatments across various therapeutic areas to address the evolving needs of patients and societies. The firm is committed to delivering high-value medicines that tackle some of the most challenging healthcare issues worldwide.

Recent filings

Filing Released Lang Actions
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to SEC rules. It contains a media release about an R&D update and investor event, discussing pipeline projects, clinical trial results, and regulatory plans. The document is a press release and event announcement rather than a full financial report or detailed investor presentation. It does not contain comprehensive financial statements or detailed management analysis. The document length is about 14,432 characters, which is substantial but the content is primarily a corporate update and media release. There is no indication that this is a full Annual Report (10-K), Interim Report (IR), or Earnings Release (ER). It is also not a Call Transcript (CT) or a Proxy Statement (PSI). The document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement and press release filed on Form 6-K, which is a catch-all for foreign issuer disclosures that do not fit other categories.
2017-11-14 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by Novartis AG, which is a report of a foreign private issuer submitted pursuant to SEC rules. The content is a media release announcing results from a new analysis of the Phase III CANTOS trial, including clinical trial data and future regulatory filing plans. It is not a full annual or quarterly report, nor is it an earnings release or management discussion. The document is a regulatory announcement providing detailed clinical trial results and forward-looking statements, typical of a regulatory filing (6-K) that supplements the annual 20-F report. It does not contain comprehensive financial statements or detailed management analysis, nor is it a proxy, capital update, or legal proceeding report. Therefore, the best classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and filings that do not fit other specific categories.
2017-11-14 English
Novartis canakinumab (ACZ885) reduced cardiovascular risk by 25% in subgroup of CANTOS Phase III trial participants
Earnings Release Classification · 95% confidence The document is a press release from Novartis dated November 13, 2017, announcing results from a new analysis of the Phase III CANTOS study, which were presented at the American Heart Association Scientific Sessions and published in The Lancet. It details clinical trial findings, safety profiles, and future regulatory filing plans ('Novartis plans to file CANTOS CV data for regulatory approval in Q4 2017'). This content is characteristic of an Earnings Release (ER) or a general announcement summarizing significant corporate/clinical news, rather than a full regulatory report (like 10-K or IR) or a specific management discussion (MDA). Since it is an initial announcement of key results, 'Earnings Release' (ER) is the most appropriate classification, even though the results are clinical rather than purely financial earnings. Q4 2017
2017-11-13 English
Novartis highlights its differentiated late stage pipeline at the R&D update and investor event
Regulatory Filings Classification · 99% confidence The document is titled 'NOVARTIS FINANCE S.A. /Novartis highlights its differentiated late stage pipeline at the R&D update and investor event' and is dated November 13, 2017. It details updates on specific late-stage pipeline projects (RTH258, AMG 334, Cosentyx, ACZ885) and discusses a proposed acquisition (AAA). This content is characteristic of an investor presentation or an update specifically designed for investors regarding R&D progress and strategy, rather than a formal regulatory filing like a 10-K or a brief earnings release (ER). The text explicitly mentions an 'R&D update and investor event' and provides background links for 'background slides and webcast'. This strongly aligns with the definition of an Investor Presentation (IP). It is not a short announcement of a report (RPA/RNS) as it contains substantial detail.
2017-11-13 English
Novartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness
Regulatory Filings Classification · 95% confidence The document is a press release from Novartis announcing positive results from Phase III clinical trials (HAWK and HARRIER) for their drug brolucizumab against aflibercept for nAMD. It details efficacy endpoints, safety profiles, and study designs. This type of announcement, which releases key financial/clinical performance highlights immediately, aligns best with the 'Earnings Release' (ER) definition, even though it concerns clinical trial data rather than quarterly revenue. However, given the context of financial reporting databases, clinical trial results announcements that drive investor sentiment are often categorized similarly to earnings releases or investor presentations. Since it is a formal announcement of results, and not a full report (10-K, IR) or a presentation (IP), and it is not a general regulatory filing (RNS), 'ER' is the closest fit for a major performance announcement. If 'ER' is strictly for financial earnings, 'RPA' (Report Publication Announcement) or 'IP' (Investor Presentation) might be considered, but the content is a direct announcement of results, not just a notice that a report is available. Given the structure and purpose (announcing key performance metrics), ER is selected as the primary classification for a major performance announcement.
2017-11-13 English
FORM 6-K
Capital/Financing Update Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to SEC rules. The content is a media release announcing the planned acquisition of Advanced Accelerator Applications, detailing the terms of the tender offer, strategic rationale, and forward-looking statements. It includes transaction details, regulatory disclaimers, and references to future filings (Schedule TO and Schedule 14D-9) that will be made when the tender offer commences. The document is not a full financial report, earnings release, or management discussion, but rather an announcement of a significant financing and acquisition activity. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed transaction information, not just a brief announcement or a report publication notice. Hence, the classification is CAP with high confidence.
2017-10-30 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.